1. Home
  2. EYPT vs EMBC Comparison

EYPT vs EMBC Comparison

Compare EYPT & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • EMBC
  • Stock Information
  • Founded
  • EYPT 1987
  • EMBC 1924
  • Country
  • EYPT United States
  • EMBC United States
  • Employees
  • EYPT N/A
  • EMBC N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • EMBC Medical/Dental Instruments
  • Sector
  • EYPT Industrials
  • EMBC Health Care
  • Exchange
  • EYPT Nasdaq
  • EMBC Nasdaq
  • Market Cap
  • EYPT 741.0M
  • EMBC 788.4M
  • IPO Year
  • EYPT 2005
  • EMBC N/A
  • Fundamental
  • Price
  • EYPT $13.76
  • EMBC $15.17
  • Analyst Decision
  • EYPT Strong Buy
  • EMBC Buy
  • Analyst Count
  • EYPT 6
  • EMBC 2
  • Target Price
  • EYPT $25.83
  • EMBC $18.50
  • AVG Volume (30 Days)
  • EYPT 823.7K
  • EMBC 490.0K
  • Earning Date
  • EYPT 11-06-2025
  • EMBC 08-08-2025
  • Dividend Yield
  • EYPT N/A
  • EMBC 3.97%
  • EPS Growth
  • EYPT N/A
  • EMBC 18.26
  • EPS
  • EYPT N/A
  • EMBC 1.42
  • Revenue
  • EYPT $51,898,000.00
  • EMBC $1,102,500,000.00
  • Revenue This Year
  • EYPT N/A
  • EMBC N/A
  • Revenue Next Year
  • EYPT N/A
  • EMBC N/A
  • P/E Ratio
  • EYPT N/A
  • EMBC $10.63
  • Revenue Growth
  • EYPT 2.99
  • EMBC N/A
  • 52 Week Low
  • EYPT $3.91
  • EMBC $9.20
  • 52 Week High
  • EYPT $14.42
  • EMBC $21.48
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 66.97
  • EMBC 65.84
  • Support Level
  • EYPT $12.88
  • EMBC $14.92
  • Resistance Level
  • EYPT $14.15
  • EMBC $15.55
  • Average True Range (ATR)
  • EYPT 0.76
  • EMBC 0.52
  • MACD
  • EYPT 0.02
  • EMBC -0.09
  • Stochastic Oscillator
  • EYPT 79.11
  • EMBC 74.15

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: